Lupin

Lupin EV/OCF

The EV/OCF (Enterprise Value to Operating Cash Flow) of Lupin (LUPIN.NS) as of Oct 18, 2026 is 12.83. In the previous year, EV/OCF (Enterprise Value to Operating Cash Flow) was 34.24 — a change of -62.53% (lower).

EV/OCF

12.83

YoY

-62.53%

Last updated:

EV/OCF (Enterprise Value to Operating Cash Flow) of Lupin is 2026 12.83 . EV/OCF (Enterprise Value to Operating Cash Flow) of Lupin was 2025 34.24 . It decreases by -62.53% lower compared to the previous year.

The Lupin EV/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/OCF
Date
EV/OCF
Jan 1, 2019
64.13 INR
Jan 1, 2020
70.26 INR
Jan 1, 2021
56.26 INR
Jan 1, 2022
281.84 INR
Jan 1, 2023
54.86 INR
Jan 1, 2024
28.02 INR
Jan 1, 2025
34.24 INR
Jan 1, 2026
12.83 INR
The Lupin EV/OCF history
YEAREV/OCFYoY
12.83-62.53%
34.24+22.21%
28.02-48.93%
54.86-80.54%
281.84+400.99%
56.26-19.93%
70.26+9.57%
64.13+5.04%
61.05+135.56%
25.92-108.87%
-292.25-899.77%
36.54-27.81%
50.62—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lupin stock

EV/OCF (Enterprise Value to Operating Cash Flow) of Lupin is 12.83 in 2026.

EV/OCF (Enterprise Value to Operating Cash Flow) of Lupin changed from 34.24 to 12.83, representing a -62.53% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/OCF (Enterprise Value to Operating Cash Flow) Lupin since 2006 – with annual values, charts, and detailed analysis.

EV/OCF compares enterprise value to operating cash flow, measuring how much investors pay per unit of cash generated from operations.

To evaluate EV/OCF (Enterprise Value to Operating Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/OCF (Enterprise Value to Operating Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/OCF (Enterprise Value to Operating Cash Flow)'s Lupin with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Lupin

All Key Metrics — Lupin